Which Innovations in the Immuno-Oncology Therapy Development Space Will Accelerate Growth?
Next-generation cell therapies and precision immunotherapies are driving growth and new product development
Overview
Immuno-oncology (I-O) therapies target tumors by harnessing the host’s immune system. The next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, including monoclonals, antibody-drug conjugates (ADCs), bispecific antibodies, and several therapeutic cancer vaccines, are making rapid strides in clinical trials as effective immunotherapy.
- What does the growth curve of the current clinical landscape of I-O therapies look like?
- Which are the technology enablers driving the growth and adoption of I-O therapies?
- What are the key developments in adoptive cell therapies and cancer vaccines driving new growth opportunities?
Quick links
Click here to preview this analysis
Already a member? Click here to access the analysis
Request More Information
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.